Phase 1b/2a Study Assessing the Safety and Efficacy of Felzartamab in Anti-Phospholipase A2 Receptor Autoantibody-Positive Primary Membranous Nephropathy

By sjmartinez • September 19, 2024

Rovin BH, Ronco PM, Wetzels JFM, Adler SG, Ayoub I, Zaoui P, Han SH, Dudani JS, Gilbert HN, Patel UD, Manser PT, Jauch-Lembach J, Faulhaber N, Boxhammer R, Härtle S, Sprangers B. Phase 1b/2a Study Assessing the Safety and Efficacy of Felzartamab in Anti-Phospholipase A2 Receptor Autoantibody-Positive Primary Membranous Nephropathy. Kidney Int Rep. 2024 Jun 20;9(9):2635-2647. doi: 10.1016/j.ekir.2024.06.018. PMID: 39291206; PMCID: PMC11403052.

Tags: Clinical Trial, felzartamab, Harbor UCLA, MOR202, Nephrology, phase 2, phospholipase A2 receptor, primary membranous nephropathy, Publications

Genome-wide Gene by Sleepiness Interaction Analysis for Sleep Apnea

Nagarajan P, Kurniansyah N, Lee J, Gharib SA, Xu Y, Zhang Y, Spitzer B, Faquih T, Zhou H, Boerwinkle E, Chen H, Gottlieb DJ, Guo[...]

Imposed expiratory resistance, dynamic hyperinflation and locomotor power and fatigue

Cunha J, Domingo A, Kolkhorst FW, Rossiter HB, Cannon DT. Imposed expiratory resistance, dynamic hyperinflation and locomotor power and fatigue. Exp Physiol. 2025 Jul 30.[...]

Experiences and perspectives of patients and their caregivers on gastrointestinal symptoms in peritoneal dialysis: Workshop report

Hayat A, Johnson DW, Manera K, Viecelli AK, Wilkie M, Shen J, Wang AY, Htay H, Jaure A, Cho Y, Walker R. Experiences and perspectives[...]